Category: Diagnostic / Testing

T2 Biosystems Inc ( TTOO )

Published: 07 August 2014
Written by Editor
Nasdaq   Up on News   New Listing  

T2 Biosystems Announces Pricing of Initial Public Offering

LEXINGTON, Mass., Aug. 7, 2014 -- T2 Biosystems, Inc. today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. All of the common stock is being offered by T2 Biosystems. In addition, T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock from the company at the public offering price. The company's shares are expected to begin trading on the NASDAQ Global Market on August 7, 2014 under the ticker symbol "TTOO."

Goldman, Sachs & Co. and Morgan Stanley & Co. are acting as joint book-running managers for the offering. Leerink Partners and Janney Montgomery Scott are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 6, 2014. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526, facsimile at (212) 902-9316, or e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it., or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by telephone at (866) 718-1649, or e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it..

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Contact:
Media Contact:
Dan Budwick, Pure Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
973-271-6085
Investor Contact:
Matt Clawson, Pure Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
949-370-8500

itial Public Offering